FindMyKOL

Steven Vogl, MD

Basic profile

Montefiore Medical Center

ORCIDNone on fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionBronx, NY · NortheastSpecialtyHematology / OncologyFocusOncology
Last active 2024FindMyKOL type: RegionalLatest publication2017Online presenceNot yet checkedPayments2021 onwardNIH funding1985–1986Why? →

Steven Vogl is an Oncology physician affiliated with Montefiore Medical Center. OpenAlex indexes 77 publications with 2,053 citations (h-index 24).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
77publications

Publications indexed by OpenAlex. Counts exclude supporting files.

2,053citations

Citations across these publications.

24h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
14companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
1NIH grants · 1985–1986

Federally funded research awards.

View funding ↓

Industry payments

14 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • TAIHO ONCOLOGY, INC.
    Program year20241 payment
    $21
  • Lilly USA, LLC
    Program year20241 payment
    $20
  • AstraZeneca Pharmaceuticals LP
    Program year20235 payments
    $110
All 23 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    43.1%
    Statin13.1%
    Pravastatin Sodium32%Rosuvastatin Calcium29%Atorvastatin Calcium21%Simvastatin18%
    Part D<11 patients
    Beta blocker9.5%
    Metoprolol Succinate46%Bisoprolol Fumarate29%Metoprolol Tartrate26%
    Part D<11 patients

    + 4 more classes in this area

  • Metabolism & gastrointestinal

    24.7%
    Potassium supplement6%
    Klor-Con M2051%Potassium Chloride49%
    Part D<11 patients
    Proton pump inhibitor4.3%
    Omeprazole100%
    Part D<11 patients

    + 6 more classes in this area

  • Cancer & immunology

    18.9%
    Aromatase Inhibitor7.2%
    Anastrozole100%
    Part D≥12 patients
    Cytochrome P450 17A1 Inhibitor5%
    Abiraterone Acetate100%
    Part D<11 patients

    + 3 more classes in this area

Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

1 NIH research award on record, funded 1985–1986 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”